It is safe to say that a significant proportion of biologics in development are being developed as injectable drugs.
Many biologics are large, complex molecules that cannot be absorbed effectively through the digestive tract, which means that they must be delivered via injection to be effective. This is particularly true for biologics used to treat conditions such as cancer, autoimmune disorders, and genetic diseases.
According to a report by Evaluate Pharma, as of 2020, the top ten biologics in development by sales potential were all injectable drugs. These included a range of drugs for cancer, autoimmune diseases, and rare genetic disorders.
It’s worth noting that the development of injectable biologics is a complex process that requires specialized manufacturing facilities and expertise. Biologic drugs must be produced using living cells, which means that their production is more complex and expensive than the production of small molecule drugs.
Overall, while it’s difficult to provide an exact number, it is clear that a significant proportion of biologics in development are being developed as injectable drugs, reflecting the importance of injectable delivery for many large, complex molecules.
